Open Access

Construction and verification of CYP3A5 gene polymorphisms using a Saccharomyces cerevisiae expression system to predict drug metabolism

  • Authors:
    • Yao Lu
    • Hua Zhong
    • Qing Tang
    • Zhijun Huang
    • Ningning Jing
    • Julie Smith
    • Rujia Miao
    • Yapei Li
    • Hong Yuan
  • View Affiliations

  • Published online on: February 17, 2017     https://doi.org/10.3892/mmr.2017.6214
  • Pages: 1593-1600
  • Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study evaluated the ability of a Saccharomyces cerevisiae expression system to predict the pharmacokinetic (PK) activity of a calcium channel blocker in patients with distinct cytochrome P450 3A5 (CYP3A5) polymorphisms. The blood pressure lowering activity of amlodipine in 57 hypertensive patients with CYP3A5*1/*1, CYP3A5*1/*3, CYP3A5*4 and CYP3A5*6 polymorphisms was evaluated by the current study. Subsequently, a Saccharomyces cerevisiae expression system for CYP3A5 gene polymorphisms was constructed to examine the PK activity of CYP3A5*1/*1, CYP3A5*4 and CYP3A5*6 polymorphisms. This system was used to predict the PK of amlodipine and was compared with the in vivo data from different gene polymorphism groups. The blood pressure lowering activity of amlodipine in hypertensive patients varied among CYP3A5 polymorphisms. The in vivo results demonstrated that CYP3A5*6 exhibited the highest metabolic rate, followed by CYP3A5*1/*1, CYP3A5*4 and CYP3A5*1/*3. The difference between CYP3A5*6 and CYP3A5*1/*1 was not statistically significant (P=0.5). In accordance with in vivo data, CYP3A5*1/*1 exhibited the highest in vitro metabolic rate, followed by CYP3A5*6 and CYP3A5*4. With the exception of the comparison between CYP3A5*6 and CYP3A5*1/*1, polymorphisms exhibited statistically significant differences compared with CYP3A5*1/*1 (P<0.05). The Saccharomyces cerevisiae expression system may be a cost effective and potentially useful tool for assessing the PK activity of drugs that are metabolized by CYP3A5.
View Figures
View References

Related Articles

Journal Cover

April-2017
Volume 15 Issue 4

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lu Y, Zhong H, Tang Q, Huang Z, Jing N, Smith J, Miao R, Li Y and Yuan H: Construction and verification of CYP3A5 gene polymorphisms using a Saccharomyces cerevisiae expression system to predict drug metabolism. Mol Med Rep 15: 1593-1600, 2017
APA
Lu, Y., Zhong, H., Tang, Q., Huang, Z., Jing, N., Smith, J. ... Yuan, H. (2017). Construction and verification of CYP3A5 gene polymorphisms using a Saccharomyces cerevisiae expression system to predict drug metabolism. Molecular Medicine Reports, 15, 1593-1600. https://doi.org/10.3892/mmr.2017.6214
MLA
Lu, Y., Zhong, H., Tang, Q., Huang, Z., Jing, N., Smith, J., Miao, R., Li, Y., Yuan, H."Construction and verification of CYP3A5 gene polymorphisms using a Saccharomyces cerevisiae expression system to predict drug metabolism". Molecular Medicine Reports 15.4 (2017): 1593-1600.
Chicago
Lu, Y., Zhong, H., Tang, Q., Huang, Z., Jing, N., Smith, J., Miao, R., Li, Y., Yuan, H."Construction and verification of CYP3A5 gene polymorphisms using a Saccharomyces cerevisiae expression system to predict drug metabolism". Molecular Medicine Reports 15, no. 4 (2017): 1593-1600. https://doi.org/10.3892/mmr.2017.6214